WO1990013641A1 - Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii - Google Patents
Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii Download PDFInfo
- Publication number
- WO1990013641A1 WO1990013641A1 PCT/US1990/002656 US9002656W WO9013641A1 WO 1990013641 A1 WO1990013641 A1 WO 1990013641A1 US 9002656 W US9002656 W US 9002656W WO 9013641 A1 WO9013641 A1 WO 9013641A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rna
- retroviral vector
- cell
- stably transformed
- foreign
- Prior art date
Links
- 239000013598 vector Substances 0.000 claims abstract description 142
- 230000001177 retroviral effect Effects 0.000 claims abstract description 82
- 210000004027 cell Anatomy 0.000 claims description 228
- 108020004414 DNA Proteins 0.000 claims description 121
- 108090000623 proteins and genes Proteins 0.000 claims description 115
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 113
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 79
- 108020005544 Antisense RNA Proteins 0.000 claims description 45
- 239000003184 complementary RNA Substances 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 41
- 230000014509 gene expression Effects 0.000 claims description 30
- 241000282414 Homo sapiens Species 0.000 claims description 25
- 244000052769 pathogen Species 0.000 claims description 24
- 230000009261 transgenic effect Effects 0.000 claims description 23
- 241001430294 unidentified retrovirus Species 0.000 claims description 23
- 230000001105 regulatory effect Effects 0.000 claims description 22
- 238000013518 transcription Methods 0.000 claims description 22
- 230000035897 transcription Effects 0.000 claims description 21
- 238000012546 transfer Methods 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 18
- 230000000295 complement effect Effects 0.000 claims description 18
- 230000001717 pathogenic effect Effects 0.000 claims description 18
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 210000004962 mammalian cell Anatomy 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 230000003053 immunization Effects 0.000 claims description 12
- 102000053602 DNA Human genes 0.000 claims description 11
- 208000031886 HIV Infections Diseases 0.000 claims description 11
- 208000037357 HIV infectious disease Diseases 0.000 claims description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 11
- 210000000130 stem cell Anatomy 0.000 claims description 11
- 208000030507 AIDS Diseases 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 9
- 108090000994 Catalytic RNA Proteins 0.000 claims description 7
- 102000053642 Catalytic RNA Human genes 0.000 claims description 7
- 241000287828 Gallus gallus Species 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 7
- 230000003394 haemopoietic effect Effects 0.000 claims description 7
- 210000005260 human cell Anatomy 0.000 claims description 7
- 108091092562 ribozyme Proteins 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 210000004102 animal cell Anatomy 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 238000013519 translation Methods 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 3
- 210000004524 haematopoietic cell Anatomy 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 description 50
- 230000000692 anti-sense effect Effects 0.000 description 45
- 230000010076 replication Effects 0.000 description 34
- 241000700605 Viruses Species 0.000 description 28
- 230000002103 transcriptional effect Effects 0.000 description 18
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 14
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- 241000894007 species Species 0.000 description 11
- 239000013615 primer Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000001052 transient effect Effects 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 239000008272 agar Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000037452 priming Effects 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 101710149951 Protein Tat Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 108091006104 gene-regulatory proteins Proteins 0.000 description 5
- 102000034356 gene-regulatory proteins Human genes 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 108020004491 Antisense DNA Proteins 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- 239000003816 antisense DNA Substances 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000005030 transcription termination Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108091092236 Chimeric RNA Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000006819 RNA synthesis Effects 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 101000929495 Homo sapiens Adenosine deaminase Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 102000043395 human ADA Human genes 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101710150344 Protein Rev Proteins 0.000 description 1
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 101800000684 Ribonuclease H Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
- C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
Definitions
- antisense inhibition RNA inhibition
- RNA complementary to DNA
- antisense RNA or DNA a complementary sequence to a portion of the target RNA.
- a duplex is formed which blocks the expression of the function or the gene encoded in
- RNA transcript through one of several possible mechanisms: degradation of the duplex; inhibition of translation; or other (11, 22, 37).
- antisense templates are capable of synthesizing antisense RNA on a continual basis when introduced into the eucaryotic cell and therefore have the potential to exert a long lasting effect on the cell and its progeny.
- Transient antisense inhibition results in the creation of a temporary state of inhibition in the cell.
- the use of antisense oligonucleotides, microinjection of antisense RNA or transient DNA transfection protocols, and use of SV40 based vectors are examples of protocols by which transient antisense inhibition is accomplished (22) .
- stable antisense RNA inhibition involves the permanent genetic alteration of the cell, achieved by the introduction of antisense templates which persist in the cell and its progeny, by synthesizing antisense RNA on a continual basis.
- the stable introduction of antisense templates into the cell can be accomplished by using any of several gene transfer techniques.
- Such techniques for the alteration of cells may involve, but are not limited to: (i) physical methods such as CaP0 4 mediated DNA transfection; (ii) electroporation; or (iii) use of viral vectors such as retroviral vectors.
- the stable form of antisense RNA inhibition has an enduring effect which creates a constant state of gene inhibition in the host cell and its progeny. It therefore provides a distinct advantage over the use of the transient protocol.
- a stable antisense inhibition protocol requires the design of a DNA template which upon transfer to the cell is capable of synthesizing adequate levels of antisense RNA to inhibit the expression of the target gene.
- the DNA template must encode an efficient transcriptional unit.
- a eucaryotic transcriptional unit comprises: (i) a promoter to initiate RNA transcription; (ii) the template of the RNA transcript; and (iii) a third region signalling RNA transcription termination.
- RNA polymerase I which transcribes riboso al genes
- RNA polymerase II which is responsible for the expression of the protein coding cellular genes
- RNA polymerase III RNA polymerase III which transcribes the 5S and t-RNA genes.
- a stable antisense inhibition protocol also requires an excess of RNA transcripts because antisense RNA inhibition requires the formation of stable duplexes between the antisense RNA and the target RNA. Indeed, several studies have shown that an apparent 30-100 fold excess of antisense RNA is required to obtain a 10-20 fold reduction in gene expression (16, 17, 20 and 26). However, other studies have shown that in some experimental systems a more moderate excess of 3-10 fold may lead to an observable inhibition (4, 21, 25 and reviewed in reference 22) .
- the effectiveness of stable and transient antisense RNA inhibition is determined by the ratio of antisense RNA to sense RNA, which in turn is determined by the efficiency of antisense RNA synthesis from the corresponding DNA template.
- pol III promoters In an attempt to improve antisense RNA synthesis using stable gene transfer protocols, the use of pol III promoters to drive the expression of antisense RNA can be considered.
- the underlying rationale for the use of pol III promoters is that they can generate substantially higher levels of RNA transcripts in cells as compared to pol II promoters. For example, it is estimated that in a eucaryotic cell there are about 6 x 10 7 t-RNA molecules and 7 x 10 5 mRNA molecules, i.e, about 100 fold more pol III transcripts of this class than total pol II transcripts (39) . Since there are about loo active t-RNA genes per cell, each t-RNA gene will generate on the average RNA transcripts equal in number to total pol II transcripts.
- a t-RNA (pol III) based transcriptional unit may be able to generate 100 fold to 10,000 fold more RNA than a pol II based transcriptional unit.
- pol III promoters to express RNA in eucaryotic cells. Lewis and Manley (23) and Sisodia (34) have fused the Adenovirus VA-1 promoter to various DNA sequences (the herpes TK gene globin and tubulin) and used transfection protocols to transfer the resulting DNA constructs into cultured cells which resulted in transient synthesis of RNA in the transduced cell.
- De la Pena and Zasloff (6) have expressed a t-RNA-Herpes TK fusion DNA construct upon microinjection into frog oocytes. Jennings and Molloy have constructed an antisense RNA template by fusing the VA-1 gene promoter to a DNA fragment derived from SV40 based vector which also resulted in transient expression of antisense RNA and limited inhibition of the target gene (18) .
- This invention provides a stably transformed eucaryotic cell comprising a pol III promoter and a foreign transcribable DNA, the foreign transcribable DNA being under the control of the pol III promoter.
- This invention also provides a retroviral vector which comprises a chimeric t-RNA introduced into the 3' long terminal repeat (LTR) of the retroviral vector.
- LTR long terminal repeat
- Figure 1 Structure of a prototype t-RNA, a human t-RNAi"*' derivative and a chimeric t-RNA gene.
- Figure 1A shows the structure of a prototype t-RNA gene.
- a t-RNA gene is 85-95 base pairs long. Two regions designated
- a and B encode the promoter which directs the initiation of
- RNA transcription to generate the primary transcript RNA transcription to generate the primary transcript.
- Termination of transcription is specified by a run of four or more T residues on the sense strand. Arrow indicates that transcription usually terminate after the third T.
- the primary t-RNA transcript is further processed to remove sequences both from the 5' end and the 3 1 end as shown, to generate the mature t-RNA transcript. (Additional modifications including addition of CCA and base modifications are not shown) . For additional information see the review by Geiduschek, 1988 (9) .
- Figure IB shows the structure of a human tRNAi"* 1 derivative 3-5.
- 3-5 was derived from a cloned human t-RNA gene by deleting 19bp from the 3' end of the gene (1).
- the truncated gene can be transcribed if a termination signal is provided, however, no processing of the 3 1 end of the primary transcript takes place.
- Figure 1C shows a chimeric t-RNA gene.
- a foreign sequence is fused to the 3' end of t-RNAi""" 3-5 and a termination signal also is added. Transcription results in the formation of a chimeric RNA species consisting of the t-RNA transcript fused to the foreign sequence.
- Figure 2 Sequence of three DNA fragments fused to t-RNAi"** 3-5.
- Figure 2 shows that the DNA fragments A and B correspond to sequence found in an HIV isolate, right to left, nucleotides 530 to 559 and 5960 to 5989, respectively (33).
- DNA fragment C corresponds to a sequence found in M-MuLV, nucleotides 1645 to 1674 (31) . Additional sequences at the 5' end of each DNA fragment generate a Sac II "sticky end” as indicated. At the 3' end of each fragment, additional nucleotides are present to generate a t-RNA transcription termination signal and a Mlul "sticky ends", as indicated.
- Figure 3 Structure of a retroviral vector containing a chimeric t-RNA gene.
- N2 is a retroviral vector derived from M-MuLV, a murine retrovirus, which was previously described (2) .
- the N2 vector was first modified by insertion of a 52 bp long polylinker sequence into the Nhel site present in the 3'LTR.
- the polylinker sequence contains five restriction sites which are unique to the N2 plasmid: Apal, Bgl II, Sna BI, Sac II, and Mlul. (14) .
- the t-RNA containing DNA fragment encoded in plasmid 3-5 (as described by Adeniyi-Jones (1)) was excised with Stu I and Bam HI, treated with Klenow fragment to generate blunt ends and cloned into the Sna BI site of the modified N2 vector.
- the three DNA fragments shown in Figure 2 were cloned into the Sac II and Mu I sites of the polylinker in the N2 vector.
- the sequences as shown in Figure 2 fused to the 3 ' end of 3-5 will generate fusion RNA transcripts in which the foreign sequence is complementary to HIV RNA (A and B) or M-MuLV (C) .
- N2 vector DNA containing the chimeric t-RNA was converted to corresponding virus using established procedures as described in text (14, 27) .
- Figure 3 also shows that in the infected cell the chimeric t-RNA is duplicated and is present in both LTR's (14). LTR - long terminal repeat; Neo-Neomycin resistance gene; 3-5- tRNAi ⁇ net derivative described in Figure IB; seq - DNA fragments described in Figure 2; T-Transcription termination signal shown in Figure 2.
- Figure 4 RNA blot analysis of cells infected with antisense vectors containing chimeric t-RNAs.
- Virus containing chimeric t-RNAs was generated by transfection of packaging cells, PA317, according to established procedures (12, 27). Total cellular RNA was isolated, subjected to electrophoresis in 8% urea- polyacrylamide gels, blotted to nitrocellulose filters and hybridized with a human t-RNAi"** probe. This probe detects both human and mouse t-RNAi"** RNA species (13) as well as the chimeric t-RNA transcripts. Panels A, B and C show that two RNA transcripts are detected in uninfected cells (NIH 3 3 panel A and B; HUT 78, panel C) . The larger species represents the primary RNA transcript in mouse cells and the shorter species is the mature t-RNA.
- RNA species which is detected with the t-RNAi 1 "" probe. This RNA species corresponds in size to the predicted size of the transcripts expressed from the corresponding templates (see Figures 2 and 3), and it is of the same size in both human and mouse cells.
- Panel A shows virus corresponding to DNA construct DCT5A and DCT5B which were used to infect NIH 3T3 cells. G418 resistant colonies were isolated and then pooled for RNA analysis. The variation in intensity of the chimeric t-RNA band is due to the variation in the fraction of cells harboring the correct vector DNA.
- Panel B shows NIH 3T3 cells infected with virus corresponding to DCT5C. G418 resistant colonies were isolated (C1-C4) and analyzed independently.
- Panel C shows HUT 78 cells infected with DCT5A virus G418 resistant colonies which were isolated in soft agar (A1-A3) and analyzed independently.
- Figure 5 Inhibition of M-MuLV replication in NIH 3T3 cells harboring antisense vectors.
- NIH 3T3 cells and a clonaly derived cell line harboring an antisense vector were infected with M-MuLV at a M.O.I, of 0.002 (10 6 cells per 6 cm plate) .
- M.O.I M.O.I 10 6 cells per 6 cm plate
- Cells were grown to semiconfluency and split 1:20. At times indicated (days 4, 6, 8 and 11) cells were removed from the plate by light tripsination and the fraction of cells harboring virus was measured by determining the presence of viral specific envelope on the cell surface using im unofluorescence staining and FACS analysis.
- the trypsinized cells were reacted with a M-MuLV envelope specific monoclonal antibody followed by FITC labelled goat antimouse antibody and sorted on a FACS machine. 10 1 fluorescence units were arbitrarily chosen to distinguish (gate) between negative and positive cells.
- the upper two panels show that in a culture of NIH 3T3 cells chronically infected with M-MuLV 91.8% cells score as positively infected cells and in a culture of uninfected NIH 3T3 cells only 1.8 score as positive, i.e. constituting the experimental background of this procedure.
- the lower left panels show that in cultures infected with a low multiplicity of virus (M.O.I. 0.002, i.e.
- HUT 78 cells were infected with DCT5A and DCT5B virus and a control virus (DCA - in which the human ADA minigene was inserted into the 3' LTR of the N2 vector) (14). Two days post-infection, the cells were plated in soft agar in the presence of 0.7 mg/ml G418. Resistant colonies appeared 10- 0 14 days later in cultures infected with the various vectors. Independent colonies were isolated and expanded to cell lines for further use.
- DCA - in which the human ADA minigene was inserted into the 3' LTR of the N2 vector 14 days post-infection, the cells were plated in soft agar in the presence of 0.7 mg/ml G418. Resistant colonies appeared 10- 0 14 days later in cultures infected with the various vectors. Independent colonies were isolated and expanded to cell lines for further use.
- Each cell line was infected with HIV (the virus strain used was ARV-2 (31), 10 5 cells per ml of 1:10 dilution of virus) ⁇ and cells were split 1:5 every three to four days. Presence of HIV in the cell cultures was determined 14 days post HIV infection by measuring the R.T. activity in the various cell lines (average of the three control cell lines is taken as zero inhibition) is indicated for each cell line harboring > an antisense vector (A1-A3 and B1-B4) . In four cell lines R.T. activity was undetectable (100% inhibition) , in two cell lines, A2 and A3, a low level of R.T activity was detected (92% and 82% inhibition, respectively) and in one cell line B3, HIV replication was not inhibited. Since RNA analysis was not performed from DCT5B containing cell lines, the most plausible explanation is that this cell line did not contain or did not express (sufficient levels) of the
- Figure 8 shows the 60 base pair oligonucleotide encoding the TAR sequence of the Human Immunodeficiency Virus (HIV) .
- HIV Human Immunodeficiency Virus
- Figure 9 shows inhibition of R.T. activity in TAR "decoy" containing cells.
- the ability of HIV to replicate in cells expressing TAR was compared to cells which were treated in parallel to contain a similar vector not expressing TAR.
- Figure 10 shows inhibition of R.T. activity in TAR "decoy" containing cells up to 24 days post infection.
- This invention provides a stably transformed eucaryotic cell, i.e., a cell into which a foreign DNA or RNA fragment was introduced so that the foreign DNA or RNA, or its transcript, or reverse transcript is maintained in the progeny over many generations, comprising a pol III promoter and a foreign transcribable DNA, the foreign transcribable DNA being under the control of the pol III promoter.
- the foreign transcribable DNA may be virtually any DNA capable of being transcribed into RNA, regardless of whether such RNA is subsequently translated into a polypeptide for example, the transcribable DNA may encode an RNA capable of acting as a false primer, i.e. a primer for the initiation of reverse transcription; and ribozyme, i.e. an enzyme made of RNA, not protein; an antisense RNA; or an mRNA, including a polypeptide translatable therefrom; or a viral regulatory sequence such as the HIV regulatory sequence designated TAR.
- the pol III promoter may be any promoter recognized by a pol III RNA polymerase.
- pol III promoters useful in the practice of this invention include, but are not limited to, t-RNA pol III promoter, such as human, plant or animal pol III promoters or mutants or derivations including chimeric derivatives thereof, e.g. a human t-RNAi"** or the 3-5 derivative thereof.
- the foreign transcribable DNA under the control of the pol III promoter may be introduced into the cell by any gene transfer method. Such methods may include, but are not limited to, the use of gene transfer vectors, CAPO 4 mediated DNA transfection or electroporation.
- the foreign transcribable DNA encodes antisense RNA which is complementary to a segment of an RNA encoded by a pathogen, such as a retrovirus, e.g. the Human Immunodeficiency Virus (HIV) or a bacteria or a parasite.
- a pathogen such as a retrovirus, e.g. the Human Immunodeficiency Virus (HIV) or a bacteria or a parasite.
- HIV Human Immunodeficiency Virus
- the transcribable DNA may encode an HIV regulatory sequence, such as the regulatory sequence designated TAR to which the HIV regulatory protein designated tat binds, to activate HIV transcription, or the REV recognition signal of HIV.
- the foreign transcribable DNA may encode a molecule which inhibits the expression of a gene within the cell such as an endogenous gene or a foreign gene, e.g. a viral or retroviral gene present within the cell.
- the foreign transcribable DNA may encode a recognition sequence of a regulator of gene expression which acts through binding to a DNA molecule, an RNA molecule, or a regulatory protein, within the cell.
- the eucaryotic cell useful in the practice of this invention may be a plant or animal cell, such as a mammalian cell, e.g. a human cell, or chicken cell.
- a mammalian cell e.g. a human cell, or chicken cell.
- the mammalian and human cells may comprise but are not limited to haematopoietic stem cells.
- the invention also provides a stably transformed eucaryotic cell comprising a pol III promoter and a foreign transcribable DNA, the transcribable DNA being under the control of the pol III promoter, wherein the pol III promoter and the foreign transcribable DNA are present in a gene transfer vector.
- the gene transfer vector may be a retroviral vector.
- the gene transfer retroviral vector also may comprise a chimeric t-RNA introduced into the 3 » long terminal repeat (LTR) region of the retroviral vector.
- the retroviral vectors useful in the practice of this invention are, but not limited to, the murine retrovirus designated M-MuLV; the retrovirus designated N2; and the double copy vectors designated DCT5A, DCT5B and DCT5C. Additionally, in accordance with the practice of this invention, the foreign DNA molecule may be under the control of a t-RNA termination signal, and the termination signal having removed therein the 3' end processing DNA sequences.
- the stably transformed eucaryotic cell may comprise two or more pol III promoters and two or more foreign transcribable DNAs, each under the control of one of the pol III promoters.
- the two or more pol III promoters may be contained within a single gene transfer vector, e.g., a retroviral vector.
- This invention further provides a retroviral vector which comprises a chimeric t-RNA introduced into the 3' long terminal repeat (LTR) of the retroviral vector.
- the chimeric t-RNA may comprise a pol III promoter and a foreign transcribable DNA, the transcribable DNA being under the control of the pol III promoter.
- the retroviral vector also may comprise two or more pol III promoters and two or more transcribable DNAs, each under the control of one of the pol in promoters.
- the foreign transcribable DNA may be virtually any DNA capable of being transcribed into RNA, regardless of whether such RNA is subsequently translated into a polypeptide, for example, the transcribable DNA may encode an RNA capable of acting as a false primer, i.e. a primer for initiation of reverse transcription; a ribozyme, i.e. an enzyme made of RNA, not protein; an antisense RNA; or an mRNA, including a polypeptide translatable therefrom; or a viral regulatory sequence such as the HIV regulatory sequence designated TAR.
- the pol III promoter may be any promoter recognized by a pol III RNA polymerase.
- pol III promoters useful in the practice of this invention include, but are not limited to, t-RNA pol III promoter, such as human, plant or animal pol III promoter or mutant or derivative including chimeric derivatives thereof, e.g. a human t-RNAi"" 4 or the 3-5 derivative thereof.
- the foreign transcribable DNA encodes antisense RNA which is complementary to a segment of an RNA encoded by a pathogen, such as a retrovirus, e.g. the Human Immunodeficiency Virus (HIV) or a bacteria or a parasite.
- a pathogen such as a retrovirus, e.g. the Human Immunodeficiency Virus (HIV) or a bacteria or a parasite.
- HIV Human Immunodeficiency Virus
- the transcribable DNA may encode an HIV regulatory sequence, e.g., the TAR sequence, or the REV recognition signal of HIV.
- the foreign transcribable DNA may encode a molecule which inhibits the expression of a gene within the cell such as an endogenous gene or a foreign gene, e.g. a viral or retroviral gene present within the cell.
- the foreign transcribable DNA may encode a recognition sequence of a regulator of gene expression which acts through binding to a DNA, an RNA molecule, or a regulatory protein, within the cell .
- the gene transfer retroviral vector also may comprise a chimeric t-RNA introduced into the 3• long terminal repeat
- the retroviral vectors useful in the practice of this invention are, but are not limited to, the murine retrovirus designated M-MuLV; the retrovirus designated N2; and the double copy vectors designated DCT5A, DCT5B and DCT5C. Additionally, in accordance with the practice of this invention, the foreign
- DNA molecule may be under the control of a t-RNA termination signal, and the termination signal having removed therein the 3' end processing DNA sequences.
- This invention further provides stably transformed animal cells; plant cells; mammalian cells, for example, mammalian and human he atopoietic stem cells; and chicken cells, each of which contain the pol III promoter and a foreign transcribable DNA, wherein the transcribable DNA is under the control of the pol III promoter, as described above.
- stably transformed cells may be contained within transgenic animals, transgenic plants, transgenic mammals and transgenic chickens, respectively.
- the transgenic animal, plant, mammal or chicken described above may contain a foreign transcribable DNA which encodes for an RNA molecule which is complementary to a segment of an RNA encoded by a pathogen.
- the pathogen may be, but is not limited to, a retrovirus such as HIV, or a bacteria or a parasite.
- a vaccine useful for immunizing a patient against HIV infection is provided by this invention which comprises an effective amount of the retroviral vector described hereinabove wherein the foreign transcribable DNA encodes an HIV regulatory sequence, for example, the HIV regulatory sequence designated TAR and a suitable carrier.
- Suitable carriers useful in the practice of this invention include, but are not limited to any pharmaceutically acceptable carrier such as sterile saline, phosphate buffered saline or an emulsion.
- This invention also provides a method of producing a foreign RNA which comprises culturing the stably transformed cells described above, under conditions permitting transcription of the transcribable DNA, thereby producing the foreign RNA. This method further provides recovering the foreign RNA molecule so produced.
- the foreign RNA molecule may comprise, but is not limited to antisense RNA, mRNA or unprocessed RNA.
- This invention further provides a method of producing a polypeptide comprising culturing the stably transformed eucaryotic cells described above under conditions permitting transcription of the transcribable DNA into RNA and translation of the RNA into a polypeptide.
- the polypeptide so produced is recovered.
- This invention also provides a method of treating an Acquired Immunodeficiency Syndrome (AIDS) patient or preventing HIV infection in a patient which comprises administering to the patient a retroviral vector as described hereinabove wherein the foreign transcribable DNA encodes for an antisense RNA molecule complementary to a segment encoded by HIV or a retroviral vector wherein the foreign transcribable DNA encodes an HIV regulatory sequence such as the sequence designated TAR.
- Suitable methods of administering the retroviral vector in pharmaceutical form are well known to those of ordinary skill in the art, and include but are not limited to administration of the retroviral vector in a pharmaceutically acceptable carrier. Suitable pharmaceutical carriers are described hereinabove.
- Suitable methods of administration include, but are not limited to administration orally, intravenously or parenterally.
- Administration of the vector must be in dose and in such a form such that the vector is transduced into the cell, so that the foreign DNA sequence is transcribed in an amount effective to inhibit HIV infection and/or replication.
- a method of intracellularly immunizing a patient against HIV infection comprises removing haematopoietic stem cells from the patient and infecting the removed stem cells with an effective amount of a retroviral vector described hereinabove wherein the foreign transcribable DNA encodes for an HIV regulatory sequence, such as the regulatory sequence designated TAR.
- the infected cells are then administered back into the patient, i.e. into the patient's bone marrow, thereby intracellularly immunizing the patient against HIV infection.
- intracellular immunization means prophylactixis as well as treatment of an infection.
- Figure 1A shows the structure of a prototype mammalian t-RNA gene (ranging in size between 95-105 bp) .
- the t-RNA promoter is encoded within the t-RNA gene itself, in two regions shown in Figure l as Box A and B. Termination of transcription is specified by a sequence present at the 3' end of the t-RNA gene (see Figure 1) which includes a run of 4 of more T nucleotides bracketed by 2 or more G or C nucleotides (on the sense strand of the DNA) . Transcription of the t-RNA gene terminates in the second or third T.
- the RNA transcribed of the t-RNA gene, the primary transcript is further processed resulting in the removal of sequences from the 5' and 3* end of the primary transcript, as shown in Figure 1 (9) .
- the human genome contains 10-12 t-RNAi"" 1 genes which are highly conserved among eucaryotes (32) (the human and mouse t-RNAi”” genes are identical and do not cross-hybridize to other cellular t-RNAs (13)) and are responsible for 10-15% of total t-RNA synthesized in mammalian cells.
- expression of RNA from one t-RNAi*" gene can be equal to or exceed the amount of total mRNA (pol II based) transcripts expressed in the cell.
- Figure IB shows the structure of a t-RNAi"** derivative, called 3-5 which was used in the studies described below.
- 3-5 contains a deletion of 19 nucleotides from the 3• end of the t-RNA gene which has effectively eliminated the 3' processing signal, i.e. the removal of the sequences 3' to the mature t-RNA (1) .
- the studies of Adeniyi-Jones (1) strongly suggests that insertion of foreign sequences between the end of the 3-5 t-RNA derivative and a termination signal will result in the synthesis of a chimeric RNA in which the bulk of the t- RNA transcript will remain fused to the foreign RNA sequence. This is illustrated in Figure 1C.
- t-RNA derivatives as well as other pol III, promoters (such as ribosomal 5S or adenovirus VAI promoters) can be used to affect the processing and/or cellular localization of the foreign RNA transcript.
- promoters such as ribosomal 5S or adenovirus VAI promoters
- t-RNAi"** derivative described by Adeniyi-Jones (1) which is called 3-2 the foreign RNA transcript will be removed and separated from the t-RNA moiety.
- t-RNAi""' mutants as described by Tobian, et al. (35) it may be possible to direct the RNA transcripts into the nucleus or cytoplasm of the cell.
- a chimeric t-RNA is a transcriptional unit formed by fusion of a oreign DNA sequence to the 3' end of a t-RNA gene or a portion of a t-RNA gene, which encodes the t-RNA promoter but lacks a transcriptional termination sequence, and a third DNA fragment fused to the 3' end of the foreign sequence which encodes a t-RNA transcription termination signal.
- three chimeric 3- 5 t-RNA genes were generated by fusing 29 and 30 bp long DNA fragments to the 3' end of 3-5, followed by a short sequence to specify termination of transcription (Figure 1C) .
- Figure 1C The sequences of the three DNA fragments are shown in Figure 2.
- the question addressed in these studies is whether stable gene transfer of the chimeric t-RNA genes into cultured cells will result in the synthesis of the corresponding RNA.
- a retroviral vector was used to introduce the chimeric t-RNA genes into cultured mouse fibroblast cells.
- Figure 3 shows the structure of the retroviral vector used, the method of cloning and the essential features of this particular vector.
- the retroviral vector is a double copy (DC) vector called N2 and is derived from M-MuLV, a murine retrovirus (12).
- the chimeric t-RNA genes were cloned into the 3' LTR to generate vector constructs DCT5A, DCT5B and DCT5C.
- the vector DNA was converted to corresponding virus and this virus was used to infect NIH 3T3 cells, an established mouse fibroblast cell line. In the infected cell it is expected that the chimeric t-RNA inserts will be duplicated and will appear in both 5' and 3* LTR as shown in Figure 3, a feature that may facilitate the expression of the hybrid t-RNA genes (14) .
- DCT5A and DCT5B vector DNAs were transfected into PA317, an amphotropic packaging cell line (27) , G418 resistant colonies were pooled and supernatant was used as a source of virus to infect NIH 3T3 cells.
- Vector infected NIH 3T3 cells were selected in G418 and pooled colonies were analyzed.
- DCT5C virus was prepared by transient transfection of PA317 cells; infection of NIH 3T3 cells with supernatant collected 48 hours post transfection; G418 selection; and isolation of individual G418 resistant colonies were analyzed as described below.
- the structure of the vector DNA integrated in the NIH 3T3 cell chromosome was determined using known DNA blotting procedures and was shown to be intact (not shown) . [As shown in Figure 3 and discussed in an article by Hantzopoulos, et al. (14) , using DC vector, the chimeric t-RNA is duplicated in the infected cell.]
- RNA blot analysis was performed to determine whether the cells harboring the chimeric t-RNA express the corresponding
- RNA in NIH 3T3 cells Total cellular RNA was subjected to electrophoresis in 8% acry ⁇ amide-urea gels, blotted to nylon filters and hybridized with a 32 P-labelled t-RNAi"** specific probe. The results of this analysis are shown in Figure 4A and 4B.
- the t-RNA probe detects two RNA species in uninfected NIH 3T3 cells in the size range of 70-90 nucleotides which represent the mature t-RNAi"** and its unprocessed form. In cells infected with the t-RNA fusion genes an additional species is detected which corresponds in size to the chimeric RNA transcripts in which the t-RNA is fused to the foreign sequence.
- the chimeric transcripts represent between 5% - 25% of total t-RNAi*** synthesized in the cell, suggesting that they are expressed very efficiently.
- t- RNAi represent 10-15% of total t-RNA, and there are 10-12 t-RNA genes per genome and t-RNAs are 100 fold more abundant than the mRNA i.e., pol II transcripts, then the chimeric t- RNA present in the cell equals (within an order of magnitude) the total number of polyA+ transcripts. This would mean that the chimeric t-RNA carrying a foreign sequence is 100 fold to 10,000 fold more abundant than individual pol II transcripts.
- chimeric t-RNA genes are not limited to the mouse fibroblast cell line NIH 3T3. Virus supernatant corresponding to DCT5A and DCT5B was used to infect HUT 78 cells, a human T-lymphoid cells line and individual clones isolated by G418 selection were analyzed for RNA expression. As shown in Figure 4C, the chimeric t-RNA genes are equally active in this human cell line.
- N2A vector Construction of the N2A vector was described previously. The 3-5 tRNAi"** gene was then cloned into the Sna BI site of the N2A vector such that transcription occurs parallel to LTR initiated transcription.
- the pol III termination sequence "Ter” was cloned between the Sac II-MluI sites of the N2A polylinker. This oligonucleotid ⁇ sequence contains a Bam HI restriction site.
- the 63 base pair TAR oligonucleotide (see Figure 8) was then cloned between the Sac II - Bam HI sites from the "Ter" oligonucleotide upstream of the pol III termination sequence.
- This TAR sequence is derived from the ARV-Z strain of HIV-I (31) .
- DCT5C contains a chimeric t-RNA gene fused to a 29 nucleotide long sequence which is complementary to a portion of M-MuLV.
- M-MuLV is a prototype murine retrovirus which replicates efficiently in NIH 3T3 cells expressing high levels of viral RNA in the cells reaching 1-5% of total polyA+ RNA (7, 36).
- the ability of DCT5C to inhibit M-MuLV replication represents a stringent test as to the potential of this new approach to inhibit the expression of genes and protect cells from the replication of viruses.
- DCT5A and DCT5B contain a chimeric t-RNA gene fused to 30 base-pair long nucleotide sequences, which upon transcription yield RNA species which are complementary to portions of the HIV genome (see Figures 2 and 3).
- the ability of the two vectors, DCT5A and DCT5B, to inhibit the replication of HIV in susceptible human lymphoid cells was tested and the results are shown in Figure 7.
- HUT 78 cells a human cutaneous T cell lymphoma derived cell line
- HUT 78 cells individually infected cells were cloned in soft agar in the presence of G418. Independently derived clones were tested for their ability to support the replication of HIV.
- HUT 78 cells were infected with a virus derived from a similar vector in which an unrelated sequence (the human adenosine deaminase minigene) was introduced into the 3'LTR of the N2 derived vector.
- the ability of HIV to replicate in HUT 78 cells containing the antisense vectors and the control vector was determined by measuring the appearance of R.T. activity in the medium.
- Figure 7 shows the result of such an experiment.
- replication of HIV cell lines harboring the DCT5A vector (A1-A3) is inhibited between the three cell lines and this correlates to the amount of antisense RNA present in the cell as can be seen in Figure 4C.
- Replication of HIV in the three cell lines harboring the vector DCT5B is virtually shut down ( Figures 7, BI, B2 and B4) .
- B3, HIV replication was not affected. The reason for that is not known.
- the ability of HIV to replicate in the HUT 78 derived cell lines was also measured using in site immunofluorescence (IFA) and the results of this experiment were consistent with R.T. analysis (not shown).
- IFA site immunofluorescence
- the experiments described in this section show that the stable transfer into cells of DNA constructs which consist of chimeric t-RNAs fused to HIV specific antisense templates, inhibit HIV replication.
- the antisense vector containing cells are protected from HIV replication, and consequently from its deleterious effects.
- the prospects of applying this methodology to human AIDS patients in which the antisense vectors are introduced into the patient to protect the patient from HIV replication and further progression of AIDS, represents an exciting and novel strategy to combat this dreadful disease (3) .
- the expression of the HIV genes is regulated by the viral gene product designated tat. Binding of the tat gene product to a specific sequence on the viral RNA, called TAR, is required for HIV gene expression and generation of virus.
- the tat recognition sequence was mapped to the 5' end of the viral RNA to encompass 60 nucleotides or less of RNA (31) .
- a 60 base pair oligonucleotide encompassing the TAR sequence was chemically synthesized, (see Figure 8) .
- a retroviral vector as shown in Figure 1-3 was constructed in which the TAR containing oligonucleotide is fused to a t-RNA gene and inserted into the 3' LTR of the M-MuLV based N2 vector. A detailed description of the construction of this vector is described hereinabove.
- clonal isolates of CEMSS cells, an HIV-l susceptible human T- ⁇ ell line harboring TAR - containing vectors or a control vector were infected with HIV-l at a multiplicity of infection (M.O.I.) of about 2.
- M.O.I. multiplicity of infection
- the ability of the vector to efficiently synthesize TAR and thereby inhibit the replication of HIV was determined by measuring the secretion of virus from the cells (determined by the appearance of reverse transcriptase (R.T.) activity in the supernatant of infected cells). As shown in Figure 9, two clonal isolates of CEMSS cells that were characterized to harbor the control vector did support HIV replication. This is documented by the appearance of reverse transcriptase (R.T.) activity in the media.
- HIV replication was significantly inhibited, i.e., in a range from 90-95% inhibition.
- Figure 10 shows the results of a separate experiment which was conducted as described above, except that R.T. activity was measured at intervals up to 24 days post infection. As can be seen in Figure 10, not only is HIV replication significantly inhibited as compared to the control at 14 days post infection, but the duration of the inhibitory effect was established up to 24 days post infection.
- RNA transcripts in eucaryotic cells in a genetically stable manner offer wide range of useful applications and a few examples are listed below.
- Antisense RNA inhibition protocols mediated via stable gene transfer can be used to render cells resistant to the replication of pathogens.
- the strategy involves the introduction, via an antisense vector, of antisense templates, i.e., a DNA molecule encoding a transcriptional unit, which upon introduction into a cell is capable of synthesizing an antisense RNA molecule, into the uninfected cell to express constitutively antisense RNA specific to a given pathogen.
- antisense templates i.e., a DNA molecule encoding a transcriptional unit
- transgenic animals and plants which carry effective antisense templates can be used to generate new animal and plant breeds which are resistant to a host of pathogens.
- Antisense RNA based strategies have been used with limited success to generate transgenic plants, in many cases achieving a level of inhibition insufficient to provide effective protection from pathogens (22) .
- pol III based promoters can be used to express in a genetically stable manner, high levels of desired RNA transcripts in the eucaryotic cell, and may be useful in the generation of animal and plant breeds carrying effective antisense templates.
- the same technology can be also used in a general way to inactivate specific genes in transgenic animal or plants. This can be used as a means to regulate various functions and properties of the transgenic breeds (21) or to introduce specific mutations to generate model systems for human genetic disorders (19) , or to investigate consequences of gene dysfunction. Additional strategies of gene inhibition which require efficient RNA synthesis
- One particular application which involves the use of a regulatory protein which functions as a competitive inhibitor to bind to an HIV protein necessary for activating transcription of HIV genes, involves the vector construct containing TAR sequences.
- bone marrow cells would be taken from a patient, including all the important haematopoietic stem cells.
- the stem cells will then be infected with the TAR-containing retroviral vector, in an amount which is effective to produce an amount of the TAR oligonucleotide decoy, such that the HIV tat protein binds to the TAR decoys and is competed away from binding to the HIV genome, thereby inhibiting the activation of transcription.
- These modified stem cells will then be injected into the patient and back to the bone marrow by methods well known to those of ordinary skill in the art. Radiation therapy or the administration of a cytotoxic drug to the patient may be used to facilitate the growth of the implanted cells.
- This "intracellular immunization" therapy would be useful not only to treat HIV positive patients, but would also be useful to prevent HIV infection.
- RNA:RNA or RNA:DNA hybrids as described by Weintraub, et al. (37), Coleman et al. (5), and van der Krol, et al. (22) .
- the common denominator of the three strategies is their dependence on the ability to express high levels of specific RNAs in the cell, which is the subject of this invention.
- the strategy of false priming involves the synthesis of specific primers which will initiate reverse transcription and virion RNA degradation at various locations throughout the viral genome, and hence lead to abrogation of the replication cycle.
- thermodynamically stable RNA:RNA hybrids The advantage of false priming as compared to antisense RNA inhibition which requires the formation of thermodynamically stable RNA:RNA hybrids is that it: (a) does not require the formation of stable hybrids; and (b) results in the irreversible inhibition (via degradation) of the target RNA.
- RNA inhibition via false priming requires the synthesis of RNA which is complementary to the target RNA throughout its 3' end (to which the DNA strand is added). Consequently, pol II based transcriptional units cannot be used to inhibit genes via false priming because pol II transcripts contains a stretch of poly A at their 3' end. On the other hand, pol III based transcriptional units are uniquely suited to inhibit genes via false priming because they can be used to generate the required RNA primers. The unique mechanism of RNA termination of pol III transcripts enables the design of specific transcripts which are complementary throughout the 3* end to a given RNA template and therefore can act as primers for reverse transcription.
- pol III terminates transcription in a run of Ts, four or more, which is bracketed by a region of G and/or C nucleotides (9) .
- the pol III transcript terminates after the second or third T. Consequently, a primer can be generated to correspond to a specific region of the retroviral genome which contains at the 3' end the sequence (G or C) 2 AAA.
- the primer sequence which can be synthesized chemically, is fused to a pol III promoter at the 5' end. At the 3' end, the primer will contain an additional sequence of two or three T nucleotides, followed by several G and/or C nucleotides to regenerate a pol III transcription termination signal.
- Haseloff and Gerlach (15) have recently shown that it is possible to cleave RNA molecules at specific sequences using artificial ribozymes. This experimental strategy can be used to inactivate specific genes by designing a transcriptional unit encoding such ribozymes.
- the HIV encoded rev gene product is a gene activator and regulates the expression of the HIV genome in the infected cell via direct binding to a specific sequence on the HIV genome called RRE (12, 24) .
- RRE a specific sequence on the HIV genome
- the rev gene will bind to this RNA and therefor will not be available for binding to the HIV RRE sequence. Consequently, the HIV genes will not be expressed, thereby inhibiting HIV production and spread.
- t-RNA promoter based RNA transcriptional units to inactivate the function of gene regulators which mediate their function by binding to specific DNA sequences. This can be achieved by designing a DNA template that generates an RNA transcript
- 1 ⁇ actual DNA sequence in the cell may compete effectively for the DNA binding protein.
- Mammalian cell based production systems are more complex, expensive and far less efficient in protein synthesis in comparison to bacterial based systems.
- the amplification process requires about 8-12 months and is fraught with uncertainties, mainly due to the frequent loss of the desired gene during the amplification process.
- the experiments described hereinabove offer an alternative approach for the large scale production of proteins in mammalian cells because it generates 100-10,000 fold higher levels of RNA transcripts in the cell as compared to conventionally employed pol II based transcriptional unit systems.
- the pol III based system can potentially produce mRNA for protein synthesis without the lengthy amplification process.
- RNA metabolism of murine leukemia virus Detection of virus-specific RNA sequences in infected cells and identification of virus-specific messenger RNA. J. Mol. Bio. 8j): 93-117.
- the HIV-l rev transactivator acts through a structures target sequence to activate nuclear export of unspliced viral mRNA. Nature 338: 254-257.
- Anti- RNA Specific inhibition of translation of single RNA molecules. Proc. Natl. Acad. Sci. USA 81: 7525-7528.
- RNAs transcribed by RNA polymerase III are not substrates for splicing or polyadenylation. Mol. Cell Biol. 2: 3602-3612.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Cell Biology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002055435A CA2055435A1 (fr) | 1989-05-10 | 1990-05-10 | Cellules eucaryotiques transformees stables comprenant un adn etranger transcriptible sous le controle d'un promoteur pol iii |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35417189A | 1989-05-10 | 1989-05-10 | |
US354,171 | 1989-05-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990013641A1 true WO1990013641A1 (fr) | 1990-11-15 |
Family
ID=23392147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/002656 WO1990013641A1 (fr) | 1989-05-10 | 1990-05-10 | Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0471796A4 (fr) |
JP (1) | JPH04505261A (fr) |
CA (1) | CA2055435A1 (fr) |
WO (1) | WO1990013641A1 (fr) |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4225094A1 (de) * | 1992-04-28 | 1993-11-04 | Frank Andreas Harald Meyer | Medikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments |
EP0596901A1 (fr) * | 1992-05-27 | 1994-05-18 | City Of Hope | MOLECULES CHIMERIQUES DE RIBOZYMES D'ARNt?LYS |
WO1994026877A1 (fr) * | 1993-05-17 | 1994-11-24 | The Regents Of The University Of California | Therapie genique ribozymique contre l'infection par le vih et contre le sida |
WO1995021912A1 (fr) * | 1994-02-14 | 1995-08-17 | The Macfarlane Burnet Centre For Medical Research Limited | Souches non pathogenes de vih-1 |
WO1995027783A1 (fr) * | 1994-04-06 | 1995-10-19 | Joshi Sukhwal Sadna | Inhibition de la multiplication du vih-1 dans des cellules de mammiferes |
US5583035A (en) * | 1992-12-07 | 1996-12-10 | Bayer Aktiengesellschaft | HIV antisense expression vectors |
US5631360A (en) * | 1992-05-14 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | N-phthaloyl-protected 2'-amino-nucleoside phosphoramdites |
US5686599A (en) * | 1992-05-14 | 1997-11-11 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US5804683A (en) * | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
US5854038A (en) * | 1993-01-22 | 1998-12-29 | University Research Corporation | Localization of a therapeutic agent in a cell in vitro |
US5871958A (en) * | 1989-05-25 | 1999-02-16 | Duke University | Mutant rev genes encoding transdominant repressors of HIV replication |
US5902880A (en) * | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US5955644A (en) * | 1996-08-08 | 1999-09-21 | M.D. Anderson Cancer Center | Ku deficient cells and non-human transgenic animals |
EP0971033A2 (fr) | 1991-01-21 | 2000-01-12 | Imperial College Of Science, Technology & Medicine | Essai et modèle pour la maladie d'Alzheimer |
US6015661A (en) * | 1994-02-14 | 2000-01-18 | The Macfarlane Burnet Centre For Medical Research Limited | Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR |
US6057489A (en) * | 1996-09-12 | 2000-05-02 | M.D. Anderson Cancer Center | MmRad51-deficient cells and transgenic mice |
US6146886A (en) * | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US6162898A (en) * | 1989-05-25 | 2000-12-19 | Duke University | Mutant Rev transdominant repressors of HIV replication |
WO2001029070A2 (fr) | 1999-10-20 | 2001-04-26 | Genentech, Inc. | Recepteur tccr de cytokine de type i |
US6437117B1 (en) | 1992-05-14 | 2002-08-20 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification for RNA and ribozymes |
US6670177B2 (en) | 1995-09-29 | 2003-12-30 | Advanced Research And Technology Institute, Inc. | Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
EP1666591A1 (fr) | 1995-06-29 | 2006-06-07 | Immunex Corporation | Cytokine induisant l'apoptose |
US7083979B1 (en) | 1994-03-25 | 2006-08-01 | Indiana University Foundation | Methods for enhanced retroviral-mediated gene transfer |
US7173115B2 (en) | 2000-01-13 | 2007-02-06 | Genentech, Inc. | Stra6 polypeptides |
EP1757618A2 (fr) | 2000-03-22 | 2007-02-28 | Curagen Corporation | Proteines associées a l'angiogenese et acides nucleiques codant pour les dites proteines |
WO2007038658A2 (fr) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Conjugues anticorps-medicament et leurs methodes d'utilisation |
EP1772515A1 (fr) | 1999-05-12 | 2007-04-11 | Immunex Corporation | Immunorégulateur de la famille nommée 'récepteurs semblables à des récepteurs de leucocytes de type immunoglobuline' (LIR) |
US7235633B2 (en) | 2000-03-21 | 2007-06-26 | Genentech, Inc. | Cytokine receptors and nucleic acids encoding the same |
EP1865061A2 (fr) | 1998-05-15 | 2007-12-12 | Genentech, Inc. | Polypeptides allogéniques IL-17 et utilisations thérapeutiques |
EP1944317A2 (fr) | 2000-09-01 | 2008-07-16 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant |
EP1953173A1 (fr) | 1999-06-15 | 2008-08-06 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant |
EP1992643A2 (fr) | 2001-06-20 | 2008-11-19 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic d'une tumeur |
EP1995321A2 (fr) | 2005-08-15 | 2008-11-26 | Genentech, Inc. | Nouvelle dislocation de gènes, compositions et procédés correspondants |
EP2002714A1 (fr) | 2005-11-21 | 2008-12-17 | Genentech, Inc. | Nouvelles ruptures génétiques, compositions et procédés associés à celles-ci |
EP2011886A2 (fr) | 2002-04-16 | 2009-01-07 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic d'une tumeur |
EP2050763A2 (fr) | 2005-03-10 | 2009-04-22 | Genentech, Inc. | Procédés et compositions de modulation d'intégrité vasculaire |
EP2050335A1 (fr) | 2006-02-17 | 2009-04-22 | Genentech, Inc. | Dislocation de gènes, compositions et procédés correspondants |
EP2067472A1 (fr) | 2002-01-02 | 2009-06-10 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic d'une tumeur |
EP2075334A1 (fr) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Acides nucléiques EG-VEGF et polypeptides et procédés d'utilisation |
EP2082645A1 (fr) | 2006-04-19 | 2009-07-29 | Genentech, Inc. | Nouvelle dislocation de gènes, compositions et procédés correspondants |
WO2009102488A2 (fr) | 2008-02-15 | 2009-08-20 | Tufts University | Modèle humanisé de la formation du complexe d’attaque membranaire (mac) sur la rétine murine et compositions, trousses et procédés de traitement de la dégénérescence maculaire |
EP2110434A1 (fr) | 2002-02-25 | 2009-10-21 | Genentech, Inc. | Recepteur de cytokine de type 1 GLM-R |
EP2143438A1 (fr) | 2001-09-18 | 2010-01-13 | Genentech, Inc. | Compositions et méthodes pour le diagnostic et le traitement de tumeurs |
US7659375B2 (en) | 1998-08-21 | 2010-02-09 | Immunex Corporation | Human IL-1 epsilon DNA and polypeptides |
EP2161283A1 (fr) | 2003-11-17 | 2010-03-10 | Genentech, Inc. | Compositions comprenant des anticorps contre le CD79b, couplés à des inhibiteurs de croissance ou à des agents cytotoxiques, et procédés pour le traitement de tumeurs d'origine hématopoïétique |
EP2163625A1 (fr) | 1999-12-23 | 2010-03-17 | Genentech, Inc. | Polypeptides homologues IL-17 et IL-17R et utilisations thérapeutiques |
US7705195B2 (en) | 2002-06-07 | 2010-04-27 | Genentech, Inc. | Screening method |
EP2186402A1 (fr) | 2005-06-06 | 2010-05-19 | Genentech, Inc. | Modèles d'animaux knock-out et leur utilisation |
EP2228446A1 (fr) | 1999-12-01 | 2010-09-15 | Genentech, Inc. | Polypeptides secrétés et transmembranaires et acides nucléiques codant pour ceux-ci |
EP2266986A1 (fr) | 2001-05-31 | 2010-12-29 | Medarex, Inc. | Cytotoxines, promedicaments, lieurs et stabilisateurs utiles pour ceux-ci |
EP2277908A2 (fr) | 2003-07-08 | 2011-01-26 | Genentech, Inc. | Polypeptides hétérologues IL-14A/F, anticorps et utilisations thérapeutiques associées |
WO2011028950A1 (fr) | 2009-09-02 | 2011-03-10 | Genentech, Inc. | Mutant smoothened et ses méthodes d'utilisation |
WO2011050194A1 (fr) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Procédés et compositions pour moduler l'activation d'hepsine d'une protéine de stimulation de macrophage |
WO2011066503A2 (fr) | 2009-11-30 | 2011-06-03 | Genentech, Inc. | Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs |
EP2333069A2 (fr) | 1998-05-15 | 2011-06-15 | Genentech, Inc. | Utilisations thérapeutiques de polypeptides homologues de IL-17 |
WO2011106297A2 (fr) | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Compositions et méthodes pour le diagnostic et le traitement d'une tumeur |
WO2011139985A1 (fr) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions et méthodes de diagnostic et de traitement d'une tumeur |
WO2012047968A2 (fr) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened et ses procédés d'utilisation |
EP2450050A1 (fr) | 2006-11-29 | 2012-05-09 | Genentech, Inc. | Polypeptides hétérologues IL-14A/F et utilisations thérapeutiques associées |
EP2614839A2 (fr) | 2006-04-05 | 2013-07-17 | Genentech, Inc. | Méthode d'utilisation du BOC/CDO pour moduler l'émission des signaux du hedgehog |
US8535912B2 (en) | 2009-10-15 | 2013-09-17 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
US8877896B2 (en) | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
WO2015116902A1 (fr) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | Récepteurs couplés aux protéines g dans la signalisation hedgehog |
WO2015120075A2 (fr) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened et méthodes d'utilisation de celui-ci |
WO2016126972A1 (fr) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened et méthodes d'utilisation de celui-ci |
EP3112468A1 (fr) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Polypeptides allogéniques il-17 et utilisations thérapeutiques |
WO2017136558A1 (fr) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened et méthodes d'utilisation dudit mutant |
EP3255144A1 (fr) | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Construction de type recombineering pour la préparation de souris transgeniques capables de produire des immunoglobulines humaines. |
US10351617B2 (en) | 2010-08-13 | 2019-07-16 | Trustees Of Tufts College | Compositions, kits and methods for treatment of complement-related disorders |
WO2019157447A1 (fr) | 2018-02-12 | 2019-08-15 | Trustees Of Tufts College | Cd59 pour inhiber l'activation d'inflammasome |
US10813977B2 (en) | 2014-08-28 | 2020-10-27 | Trustees Of Tufts College | Compositions, methods and kits for treating complement related disorders |
WO2023089564A1 (fr) | 2021-11-19 | 2023-05-25 | Janssen Biotech, Inc. | Méthode de traitement d'une atrophie géographique avec un vecteur de thérapie génique exprimant cd59 soluble |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59010432D1 (de) * | 1989-03-16 | 1996-09-05 | Boehringer Ingelheim Int | Genetische Einheiten zur Inhibierung der Funktion von RNA |
-
1990
- 1990-05-10 CA CA002055435A patent/CA2055435A1/fr not_active Abandoned
- 1990-05-10 WO PCT/US1990/002656 patent/WO1990013641A1/fr not_active Application Discontinuation
- 1990-05-10 EP EP19900909233 patent/EP0471796A4/en not_active Withdrawn
- 1990-05-10 JP JP2508724A patent/JPH04505261A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
Non-Patent Citations (13)
Title |
---|
Cell, Volume 43, published December 1985. J. TOBIAN, et al. "tRNA nuclear transport: defining the critical regions of human tRNA (i)(met) by point mutagenesis" pp. 415-422. see entire article. * |
CHEMICAL ABSTRACTS, Volume 111, No. 13, issued 1989, September 25 (Columbus, Ohio, U.S.A.), E. GILBOA, et al. "Retroviral gene transfer: applications to human therapy" see page 110247, column 1, the Abstract No. 110249f, Adv. Exp. Biol. Med. 1988, 241 (Mol. Biol. Hemopoesis), 29-33 (Eng). * |
Cold Spring Harbor Sym. on Mol. Biol., Volume LI. published 1986. A. MILLER, et al. "Transfer of genes into human somatic cells using retrovirus vectors" pp. 1013-1019. see entire article. * |
EMBO J., Volume 6, Number 10, published October 1987. P. JENNINGS, et al. "Inhibition of SV40 replicon function by engineered antisense RNA transcribed by RNA polymerase III" pp. 3043-3047. see entire article. * |
EMBO J., Volume 6, Number 2, published February 1987. N. TAKAMATSU, et al. "Expression of bacterial chloramphenicol acetyltransferase gene in tobacco plants mediated by TMV-RNA" pp. 307-311. see entire article. * |
J. Virol., Volume 63, Number 2, published February 1989. T. VON RUDEN, et al. "Inhibition of human T-cell leukemia virus type I replication in primary human T cells that express antisense RNA" pp. 677-682. see entire article. * |
J. Virol., Volume 63, Number 3, published March 1989. M. HADZOPOULOU-CLADARAS, et al. "The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region" pp. 1265-1274 see entire article. * |
Nature, Volume 323, published 25 September 1986. J. ZARLING, et al. "T-cell responses to human AIDS virus in macaques immunized with recombinant virus" pp. 344-346. see entire article. * |
Nature, Volume 335, published 29 September 1988. A. FRIEDMAN, et al. "Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus" pp. 452-454. see entire article. * |
Nature, Volume 335, published 29 September 1988. D. BALTIMORE "Intracellular Immunization" pp. 395-396. see entire article. * |
Nucl. Acid. Res., Volume 11, Number 6, published 1983. D.JOLLY, et al. "Elements in the long terminal repeat of murine retroviruses stable transformation by thymidine kinase gene", pp. 1855-1872. see entire document. * |
Nucl. Acid. Res., Volume 12, Number 2, published 1984. S. ADENIYI-JONES, et al. "Generation of long read-through transcripts in vivo and in vitro by deletion of 3' termination and processing sequences in the human tRNA (i)(met) gene" pp. 1101-1115. see entire article. * |
See also references of EP0471796A4 * |
Cited By (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5871958A (en) * | 1989-05-25 | 1999-02-16 | Duke University | Mutant rev genes encoding transdominant repressors of HIV replication |
US6287809B1 (en) | 1989-05-25 | 2001-09-11 | Novartis Ag | Mutant rex transdominant repressors of HIV replication |
US6251675B1 (en) | 1989-05-25 | 2001-06-26 | Duke University | Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication |
US6162898A (en) * | 1989-05-25 | 2000-12-19 | Duke University | Mutant Rev transdominant repressors of HIV replication |
US6339150B1 (en) | 1989-07-07 | 2002-01-15 | Duke University | Mutant rex genes encoding transdominant repressors of HIV/HTLV replication |
EP0971033A2 (fr) | 1991-01-21 | 2000-01-12 | Imperial College Of Science, Technology & Medicine | Essai et modèle pour la maladie d'Alzheimer |
DE4225094A1 (de) * | 1992-04-28 | 1993-11-04 | Frank Andreas Harald Meyer | Medikament zur gentherapeutischen behandlung von menschen, tieren und pflanzen, insbesondere zur blockierung der virenvermehrung und der tumorgene sowie verfahren zur herstellung des medikaments |
US5631360A (en) * | 1992-05-14 | 1997-05-20 | Ribozyme Pharmaceuticals, Inc. | N-phthaloyl-protected 2'-amino-nucleoside phosphoramdites |
US6437117B1 (en) | 1992-05-14 | 2002-08-20 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification for RNA and ribozymes |
US5686599A (en) * | 1992-05-14 | 1997-11-11 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US5804683A (en) * | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
US5831071A (en) * | 1992-05-14 | 1998-11-03 | Ribozyme Pharmaceuticals, Inc. | Synthesis deprotection analysis and purification of RNA and ribozymes |
US6649751B2 (en) | 1992-05-14 | 2003-11-18 | Sirna Therapeutics, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US7041817B2 (en) | 1992-05-14 | 2006-05-09 | Sirna Therapeutics, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US6353098B1 (en) | 1992-05-14 | 2002-03-05 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
EP0596901A4 (en) * | 1992-05-27 | 1995-11-15 | Hope City | Chimeric trna?lys -ribozyme molecules. |
EP0596901A1 (fr) * | 1992-05-27 | 1994-05-18 | City Of Hope | MOLECULES CHIMERIQUES DE RIBOZYMES D'ARNt?LYS |
US5583035A (en) * | 1992-12-07 | 1996-12-10 | Bayer Aktiengesellschaft | HIV antisense expression vectors |
US5854038A (en) * | 1993-01-22 | 1998-12-29 | University Research Corporation | Localization of a therapeutic agent in a cell in vitro |
US6132962A (en) * | 1993-05-17 | 2000-10-17 | The Regents Of The University Of California | Retroviral vectors comprising an anti-hiv or other nucleic acid |
US5670361A (en) * | 1993-05-17 | 1997-09-23 | The Regents Of The University Of California | HIV-specific ribozymes |
WO1994026877A1 (fr) * | 1993-05-17 | 1994-11-24 | The Regents Of The University Of California | Therapie genique ribozymique contre l'infection par le vih et contre le sida |
WO1995021912A1 (fr) * | 1994-02-14 | 1995-08-17 | The Macfarlane Burnet Centre For Medical Research Limited | Souches non pathogenes de vih-1 |
US6015661A (en) * | 1994-02-14 | 2000-01-18 | The Macfarlane Burnet Centre For Medical Research Limited | Methods for the detection of non-pathogenic HIV-1 strains containing deletions in the Nef coding region and U3 region of the LTR |
US7083979B1 (en) | 1994-03-25 | 2006-08-01 | Indiana University Foundation | Methods for enhanced retroviral-mediated gene transfer |
US7759467B2 (en) | 1994-03-25 | 2010-07-20 | Indiana University Research And Technology Corporation | Enhanced mediated DNA transfer |
WO1995027783A1 (fr) * | 1994-04-06 | 1995-10-19 | Joshi Sukhwal Sadna | Inhibition de la multiplication du vih-1 dans des cellules de mammiferes |
US6852535B1 (en) | 1994-08-19 | 2005-02-08 | Sirna Therapeutics, Inc. | Polymerase III-based expression of therapeutic RNAS |
US6146886A (en) * | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US5902880A (en) * | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
EP1666591A1 (fr) | 1995-06-29 | 2006-06-07 | Immunex Corporation | Cytokine induisant l'apoptose |
US6670177B2 (en) | 1995-09-29 | 2003-12-30 | Advanced Research And Technology Institute, Inc. | Methods for enhanced virus-mediated DNA transfer using molecules with virus-and cell-binding domains |
US8889419B2 (en) | 1995-09-29 | 2014-11-18 | Indiana University Research & Technology Corporation | Methods for enhanced virus-mediated DNA transfer using molecules with virus- and cell-binding domains |
US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
US5955644A (en) * | 1996-08-08 | 1999-09-21 | M.D. Anderson Cancer Center | Ku deficient cells and non-human transgenic animals |
US6057489A (en) * | 1996-09-12 | 2000-05-02 | M.D. Anderson Cancer Center | MmRad51-deficient cells and transgenic mice |
EP1865061A2 (fr) | 1998-05-15 | 2007-12-12 | Genentech, Inc. | Polypeptides allogéniques IL-17 et utilisations thérapeutiques |
EP3112468A1 (fr) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Polypeptides allogéniques il-17 et utilisations thérapeutiques |
EP2333069A2 (fr) | 1998-05-15 | 2011-06-15 | Genentech, Inc. | Utilisations thérapeutiques de polypeptides homologues de IL-17 |
US7659375B2 (en) | 1998-08-21 | 2010-02-09 | Immunex Corporation | Human IL-1 epsilon DNA and polypeptides |
EP1772515A1 (fr) | 1999-05-12 | 2007-04-11 | Immunex Corporation | Immunorégulateur de la famille nommée 'récepteurs semblables à des récepteurs de leucocytes de type immunoglobuline' (LIR) |
EP1953173A1 (fr) | 1999-06-15 | 2008-08-06 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant |
EP1956030A1 (fr) | 1999-06-15 | 2008-08-13 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant |
WO2001029070A2 (fr) | 1999-10-20 | 2001-04-26 | Genentech, Inc. | Recepteur tccr de cytokine de type i |
EP2228446A1 (fr) | 1999-12-01 | 2010-09-15 | Genentech, Inc. | Polypeptides secrétés et transmembranaires et acides nucléiques codant pour ceux-ci |
EP2258848A1 (fr) | 1999-12-23 | 2010-12-08 | Genentech, Inc. | Polypeptides allogéniques IL-17 et utilisations thérapeutiques |
EP2163625A1 (fr) | 1999-12-23 | 2010-03-17 | Genentech, Inc. | Polypeptides homologues IL-17 et IL-17R et utilisations thérapeutiques |
EP2290081A2 (fr) | 1999-12-23 | 2011-03-02 | Genentech, Inc. | Polypeptides allogéniques IL-17 et utilisations thérapeutiques |
US7855278B2 (en) | 2000-01-13 | 2010-12-21 | Genentech, Inc. | Antibodies to Stra6 polypeptides |
US7939650B2 (en) | 2000-01-13 | 2011-05-10 | Genentech, Inc. | Stra6 polypeptides |
US7741439B2 (en) | 2000-01-13 | 2010-06-22 | Genentech, Inc. | Isolated stra6 polypeptides |
US7173115B2 (en) | 2000-01-13 | 2007-02-06 | Genentech, Inc. | Stra6 polypeptides |
US7235633B2 (en) | 2000-03-21 | 2007-06-26 | Genentech, Inc. | Cytokine receptors and nucleic acids encoding the same |
EP1757618A2 (fr) | 2000-03-22 | 2007-02-28 | Curagen Corporation | Proteines associées a l'angiogenese et acides nucleiques codant pour les dites proteines |
EP2075334A1 (fr) | 2000-06-23 | 2009-07-01 | Genentech, Inc. | Acides nucléiques EG-VEGF et polypeptides et procédés d'utilisation |
EP1944317A2 (fr) | 2000-09-01 | 2008-07-16 | Genentech, Inc. | Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant |
EP2266986A1 (fr) | 2001-05-31 | 2010-12-29 | Medarex, Inc. | Cytotoxines, promedicaments, lieurs et stabilisateurs utiles pour ceux-ci |
EP1992643A2 (fr) | 2001-06-20 | 2008-11-19 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic d'une tumeur |
EP2000148A1 (fr) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic du cancer de la prostate |
EP2000545A1 (fr) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic d'une tumeur |
EP2000482A1 (fr) | 2001-06-20 | 2008-12-10 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic d'une tumeur |
EP2143438A1 (fr) | 2001-09-18 | 2010-01-13 | Genentech, Inc. | Compositions et méthodes pour le diagnostic et le traitement de tumeurs |
EP2151244A1 (fr) | 2001-09-18 | 2010-02-10 | Genentech, Inc. | Compositions et méthodes pour le diagnostic et le traitement de tumeurs |
EP2153843A1 (fr) | 2001-09-18 | 2010-02-17 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic d'une tumeur |
EP2067472A1 (fr) | 2002-01-02 | 2009-06-10 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic d'une tumeur |
EP2110434A1 (fr) | 2002-02-25 | 2009-10-21 | Genentech, Inc. | Recepteur de cytokine de type 1 GLM-R |
EP2011886A2 (fr) | 2002-04-16 | 2009-01-07 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic d'une tumeur |
US7705195B2 (en) | 2002-06-07 | 2010-04-27 | Genentech, Inc. | Screening method |
EP3594228A1 (fr) | 2003-07-08 | 2020-01-15 | Genentech, Inc. | Polypeptides hétérologues il-14a/f et utilisations thérapeutiques associées |
EP2784084A1 (fr) | 2003-07-08 | 2014-10-01 | Genentech, Inc. | Polypeptides hétérologues IL-17 A/F et utilisations thérapeutiques associées |
EP2277908A2 (fr) | 2003-07-08 | 2011-01-26 | Genentech, Inc. | Polypeptides hétérologues IL-14A/F, anticorps et utilisations thérapeutiques associées |
EP2295073A1 (fr) | 2003-11-17 | 2011-03-16 | Genentech, Inc. | Anticorps dirigé contre CD22 pour le traitement de tumeurs d'origine hématopoïétique |
EP2161283A1 (fr) | 2003-11-17 | 2010-03-10 | Genentech, Inc. | Compositions comprenant des anticorps contre le CD79b, couplés à des inhibiteurs de croissance ou à des agents cytotoxiques, et procédés pour le traitement de tumeurs d'origine hématopoïétique |
EP2301568A1 (fr) | 2003-11-17 | 2011-03-30 | Genentech, Inc. | Anticorps dirigé contre IRTA2 pour le traitement de tumeurs d'origine hématopoïétique |
EP2050763A2 (fr) | 2005-03-10 | 2009-04-22 | Genentech, Inc. | Procédés et compositions de modulation d'intégrité vasculaire |
EP2186402A1 (fr) | 2005-06-06 | 2010-05-19 | Genentech, Inc. | Modèles d'animaux knock-out et leur utilisation |
EP1995321A2 (fr) | 2005-08-15 | 2008-11-26 | Genentech, Inc. | Nouvelle dislocation de gènes, compositions et procédés correspondants |
WO2007038658A2 (fr) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Conjugues anticorps-medicament et leurs methodes d'utilisation |
EP2354163A2 (fr) | 2005-09-26 | 2011-08-10 | Medarex, Inc. | Conjugué d'un anticorps anti-cd4 ou anti-psma et duocarmycine |
EP2002714A1 (fr) | 2005-11-21 | 2008-12-17 | Genentech, Inc. | Nouvelles ruptures génétiques, compositions et procédés associés à celles-ci |
EP2050335A1 (fr) | 2006-02-17 | 2009-04-22 | Genentech, Inc. | Dislocation de gènes, compositions et procédés correspondants |
EP2614839A2 (fr) | 2006-04-05 | 2013-07-17 | Genentech, Inc. | Méthode d'utilisation du BOC/CDO pour moduler l'émission des signaux du hedgehog |
EP2082645A1 (fr) | 2006-04-19 | 2009-07-29 | Genentech, Inc. | Nouvelle dislocation de gènes, compositions et procédés correspondants |
EP2450050A1 (fr) | 2006-11-29 | 2012-05-09 | Genentech, Inc. | Polypeptides hétérologues IL-14A/F et utilisations thérapeutiques associées |
EP3181147A1 (fr) | 2006-11-29 | 2017-06-21 | Genentech, Inc. | Polypeptides hétérodimères il -17 a/f et leurs thérapeutiques |
EP3255144A1 (fr) | 2007-08-10 | 2017-12-13 | E. R. Squibb & Sons, L.L.C. | Construction de type recombineering pour la préparation de souris transgeniques capables de produire des immunoglobulines humaines. |
WO2009102488A2 (fr) | 2008-02-15 | 2009-08-20 | Tufts University | Modèle humanisé de la formation du complexe d’attaque membranaire (mac) sur la rétine murine et compositions, trousses et procédés de traitement de la dégénérescence maculaire |
US8324182B2 (en) | 2008-02-15 | 2012-12-04 | Tufts University | Humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration |
US8877896B2 (en) | 2008-02-15 | 2014-11-04 | Tufts University | Compositions, methods and kits for modeling, diagnosing, and treating complement disorders |
WO2011028950A1 (fr) | 2009-09-02 | 2011-03-10 | Genentech, Inc. | Mutant smoothened et ses méthodes d'utilisation |
US8535912B2 (en) | 2009-10-15 | 2013-09-17 | Genentech, Inc. | Chimeric fibroblast growth factors with altered receptor specificity |
WO2011050194A1 (fr) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Procédés et compositions pour moduler l'activation d'hepsine d'une protéine de stimulation de macrophage |
WO2011066503A2 (fr) | 2009-11-30 | 2011-06-03 | Genentech, Inc. | Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs |
EP3002297A2 (fr) | 2009-11-30 | 2016-04-06 | F. Hoffmann-La Roche AG | Anticorps pour le traitement et la diagnose du tumeurs exprimant slc34a2 (tat211) |
WO2011106297A2 (fr) | 2010-02-23 | 2011-09-01 | Genentech, Inc. | Compositions et méthodes pour le diagnostic et le traitement d'une tumeur |
WO2011139985A1 (fr) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions et méthodes de diagnostic et de traitement d'une tumeur |
US10351617B2 (en) | 2010-08-13 | 2019-07-16 | Trustees Of Tufts College | Compositions, kits and methods for treatment of complement-related disorders |
WO2012047968A2 (fr) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened et ses procédés d'utilisation |
WO2015116902A1 (fr) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | Récepteurs couplés aux protéines g dans la signalisation hedgehog |
WO2015120075A2 (fr) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened et méthodes d'utilisation de celui-ci |
US10813977B2 (en) | 2014-08-28 | 2020-10-27 | Trustees Of Tufts College | Compositions, methods and kits for treating complement related disorders |
EP3892291A1 (fr) | 2014-08-28 | 2021-10-13 | Tufts University | Compositions, procédés et kits pour le traitement des troubles liés au complément |
US11654179B2 (en) | 2014-08-28 | 2023-05-23 | Trustees Of Tufts College | Compositions, methods and kits for treating complement related disorders |
WO2016126972A1 (fr) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened et méthodes d'utilisation de celui-ci |
WO2017136558A1 (fr) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened et méthodes d'utilisation dudit mutant |
EP4442320A2 (fr) | 2018-02-12 | 2024-10-09 | Trustees Of Tufts College | Procédés d'inhibition de l'activation d'inflammasome |
WO2019157447A1 (fr) | 2018-02-12 | 2019-08-15 | Trustees Of Tufts College | Cd59 pour inhiber l'activation d'inflammasome |
WO2023089564A1 (fr) | 2021-11-19 | 2023-05-25 | Janssen Biotech, Inc. | Méthode de traitement d'une atrophie géographique avec un vecteur de thérapie génique exprimant cd59 soluble |
Also Published As
Publication number | Publication date |
---|---|
JPH04505261A (ja) | 1992-09-17 |
EP0471796A1 (fr) | 1992-02-26 |
EP0471796A4 (en) | 1993-05-05 |
CA2055435A1 (fr) | 1990-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1990013641A1 (fr) | Cellules eucaryotes transformees de maniere stable comprenant un adn etranger susceptible d'etre transcrit sous la direction d'un promoteur pol iii | |
Dropulić et al. | Functional characterization of a U5 ribozyme: intracellular suppression of human immunodeficiency virus type 1 expression | |
McNALLY et al. | Intronic sequences and 3'splice sites control Rous sarcoma virus RNA splicing | |
US20020160393A1 (en) | Double-stranded RNA-mediated gene suppression | |
EP3132683A1 (fr) | Procédé d'expression de petites molécules d'arn dans une cellule | |
JP2746480B2 (ja) | 遺伝子発現に影響を与える多重標的応答因子をもつベクター | |
WO1993011230A1 (fr) | Cellule souche modifiee de mammifere bloquant la replication virale | |
Arrigo et al. | cis-Acting regulatory elements within gag genes of avian retroviruses | |
To et al. | Inhibition of retroviral replication by anti-sense RNA | |
JPH06335392A (ja) | Hiv阻害性アンチセンスおよび他のヌクレオチド配列を含有する発現構成体、レトロウイルスのベクターおよびそれを含有する組換えレトロウイルス | |
DE69534864T2 (de) | Ribozyme gegen eine HIV Tat Sequenz | |
Gdovin et al. | Molecular mechanisms of visna virus Tat: identification of the targets for transcriptional activation and evidence for a post-transcriptional effect | |
Biasolo et al. | A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection | |
WO1992017211A1 (fr) | Inhibition d'un retrovirus a l'aide d'acides nucleiques non codants s'hybridant sur des sequences d'encapsidation | |
WO1994016060A1 (fr) | Mutants de vih destines a la suppression des infections par vih | |
US6245560B1 (en) | Vector with multiple target response elements affecting gene expression | |
AU703964B2 (en) | Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs | |
DE60033517T2 (de) | Invivo selektionsverfahren zur bestimmung von inhibierenden rna molekülen | |
US5753490A (en) | Recombinant HIV and modified packaging cells and method for treating acquired immune deficiency syndrome | |
US6063374A (en) | Recombinant HIV and modified packaging cells and method for using | |
AU2002246742B2 (en) | Double-stranded RNA-mediated gene suppression | |
MERGIA et al. | Inhibition of FIV replication by a ribozyme that targets the Rev response element | |
Kim et al. | Examination of antisense RNA and oligodeoxynucleotides as potential inhibitors of avian leukosis virus replication in RP30 cells | |
Andäng et al. | Cis-cleavage affects hammerhead and hairpin ribozyme steady-state levels differently and has strong impact on trans-targeting efficiency | |
AU2002246742A1 (en) | Double-stranded RNA-mediated gene suppression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2055435 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990909233 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990909233 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990909233 Country of ref document: EP |